MARKET WIRESeeking Alpha • 18h ago
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product (BRVE)Seeking Alpha report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
Why BRVE Stock advanced +1.51% Today — RQD Quant Desk Flash
$21.51 +1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.53
Braveheart Bio Inc. (BRVE) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.94B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BRVE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $21.51 (+1.51% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BRVE ranks #326 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BRVE compare to TRVI and XERS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.93B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BRVE?
▼
Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.53 (+0.08%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRVE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY BRVE SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 1.4% FCF Margin ($54.2M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$19.33+4.9% Next Q
38
Q2 (-2Q)Grade D$20.27+7.6% Next Q
41
Q3 (-1Q)Grade D$21.82-1.4% Next Q
43
CurrentGrade D$21.51-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BRVE Turnaround Squeeze
While BRVE currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.27) and Max Pain ($22.59) forces dealer call-delta covering toward $33.60.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRVE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BRVE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BRVE Stock advanced +1.51% Today — RQD Quant Desk Flash
Braveheart Bio Inc. (BRVE) advanced +1.51% to $21.51, trading at 26% of its 52-week range ($17.86 – $32). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 26% of its 52-week range ($17.86 – $32) with RSI-14 at 49.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $21.51 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $54.2M annual free cash flow.
Live BRVE Headlines & Catalysts
MARKET WIRESimply Wall St • 21h ago
Braveheart Bio (NasdaqGM:BRVE) Stock Forecast & Analyst PredictionsSimply Wall St report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A heart drug’s 52-week results are headed for a late-breaking presentationStock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Braveheart Bio (NASDAQ:BRVE) Shares Down 7.6% - Time to Sell?MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Braveheart Bio to Host Investor and Analyst Webinar on BHB-1893 and Hypertrophic Cardiomyopathy ProgramQuiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two heart doctors will discuss Braveheart Bio's developing treatment for a condition that thickens heart muscle.Stock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Braveheart Bio (NASDAQ:BRVE) Stock Price Up 7.9% - Should You Buy?MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Braveheart Bio Announces Upcoming AHA 2026 Presentations, Including 52-Week Extension Data for BHB-1893 in Obstructive HCMQuiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser
MARKET WIREYahoo • 3d ago
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRVE)
- ✓Walkthrough of BRVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BRVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.82%▼ DESCENDING CHANNEL
2026-11-03O $21.19H $21.51L $21.19C $21.51VOL 533.7K
RES: $26.64SUP: $13.56SMA50: $23.27SMA200: $24.14
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BRVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BRVE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BRVE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BRVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRVE)
Health Care Rank #326 of 1016
⚔️ TRVI vs BRVE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BRVE vs. TRVI, XERS, SLS, SRPT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Braveheart Bio Inc. (BRVE) ranks #326 by composite RQD confidence (46/100, grade D) and #261 by equity capitalization ($1.94B). Within this direct 5-issuer industry benchmark cohort, BRVE leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with BRVE at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BRVE
ACTIVE
Braveheart Bio Inc. | D | 46/100 | — | — | — | +1.51% | $1.94B | Benchmark Subject |
| TRVI Trevi Therapeutics Inc. | E | 30/100 | — | — | -23.7% | -1.81% | $1.93B | /trvi-vs-brve → |
| XERS Xeris Biopharma Holdings Inc. | C | 64/100 | — | — | 16.0% | -0.37% | $1.95B | /xers-vs-brve → |
| SLS SELLAS Life Sciences Group Inc. | D- | 38/100 | — | — | -21.8% | -4.68% | $1.95B | /sls-vs-brve → |
| SRPT Sarepta Therapeutics Inc. | E | 27/100 | — | 96.0% | -35.0% | -3.17% | $1.97B | /srpt-vs-brve → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002131524In its most recent audited fiscal period (FY2025, filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BRVE closed FY2025 with $89.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $89.3M | — |
3. BRVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $21.51 (+1.51% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BRVE ranks #326 in composite RQD confidence.
How does BRVE compare to TRVI and XERS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.93B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BRVE?
Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BRVE trading relative to its 50-day, 200-day, and 52-week technical levels?
BRVE last traded at $21.51 (+1.51% on volume of 533,674 shares), positioning the stock -7.56% below its 50-day simple moving average ($23.27) and -10.89% below its 200-day simple moving average ($24.14). Across its 52-week range of $17.86 to $32.00, BRVE sits at the 25.8% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.82 to $24.20).
BRVE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BRVE stock moving today?
Why BRVE Stock advanced +1.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BRVE — Braveheart Bio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:12:52Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 46 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars are:
- Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, this reflects ROIC of 0% and FCF yield of 0%. For a prospective investor, the rating indicates no measurable return on invested capital and no free-cash-flow yield in the source data.
- Whale / 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. Its low score points to weak institutional support in the source data, though no holder-level detail is provided in
<holders>. - Insider Conviction: 9 / 20. Per the Roarable RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The source data does not include the underlying transactions, so the score cannot be traced to specific trades.
- Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity component. A beta of 1.0 means the stock is rated as moving in line with the market, and the score indicates limited regime-fit advantage.
- Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a comparatively sounder balance sheet than the other four pillars.
Taken together, the rating points to a weak cash-generation profile and weak institutional and insider signals, partly offset by balance-sheet resilience. A prospective investor would weigh the upside drivers (balance-sheet strength, the 52-week high of $32 as a reference point) against valuation tradeoffs, since no earnings-based valuation multiples are available in the source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | $89.2M | N/A |
Per the SEC financials, reported revenue, operating income, and net income are all $0.0M for FY 2025, and gross, operating, and net margins are 0% (per the market data). ROIC is 0% and FCF yield is 0% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. Reported cash is $89.2M, while the debt figure is listed as N/A in the SEC financials.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the catalysts are headline-level items, all flagged YELLOW under the MARKET WIRE impact label:
- Seeking Alpha coverage of the stock's non-obstructive HCM therapeutic window (published roughly 1 hour before the data timestamp).
- Simply Wall St coverage with a forecast and analyst-predictions framing.
- Stock Titan coverage of 52-week results for a heart drug being slated for a late-breaking presentation.
- MarketBeat coverage reporting shares down 7.6%.
- Quiver Quantitative coverage of an investor and analyst webinar on BHB-1893 and the hypertrophic cardiomyopathy program.
- Stock Titan coverage of two cardiologists discussing the developing treatment for a heart-muscle-thickening condition.
Risk watch items in this feed include the reported 7.6% share decline and the price action captured in the market data (change of -2.62% on the day). The Butterfly graph reports no proprietary signals.
Open Questions
- What products or clinical programs generate BRVE's economics, and what is the revenue path given $0.0M reported revenue for FY 2025?
- What is the debt figure, given the financials list debt as N/A while Debt/Equity is cited as 0.5?
- What specific institutional and insider transactions underlie the 5/20 whale-flow and 9/20 insider-conviction pillars?
- What drove the 7.6% share decline referenced in the MarketBeat coverage, and how does it relate to the 52-week range of $17.86 to $32?
- What are the reported EPS, free cash flow, and earnings-based valuation multiples, which the source data marks as unavailable?
BRVE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Braveheart Bio Inc. (BRVE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 18h ago
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product (BRVE) Seeking Alpha report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 21h ago
Braveheart Bio (NasdaqGM:BRVE) Stock Forecast & Analyst Predictions Simply Wall St report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A heart drug’s 52-week results are headed for a late-breaking presentation Stock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Braveheart Bio (NASDAQ:BRVE) Shares Down 7.6% - Time to Sell? MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Braveheart Bio to Host Investor and Analyst Webinar on BHB-1893 and Hypertrophic Cardiomyopathy Program Quiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two heart doctors will discuss Braveheart Bio's developing treatment for a condition that thickens heart muscle. Stock Titan report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Braveheart Bio (NASDAQ:BRVE) Stock Price Up 7.9% - Should You Buy? MarketBeat report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Braveheart Bio Announces Upcoming AHA 2026 Presentations, Including 52-Week Extension Data for BHB-1893 in Obstructive HCM Quiver Quantitative report covering Braveheart Bio Inc. (BRVE) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BRVE Bull vs. Bear Conversation Board — What's Your Call at $21.51?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BRVE 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $22.89 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BRVE (D • RQD 46/100) a Buy at $21.19?
Welcome to the BRVE (Braveheart Bio Inc.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $17.38 (-18.0%)
Spot @ $21.19 Pump the brakes on BRVE — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BRVE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Braveheart Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $25.64 (+21.0%)
Spot @ $21.19 BRVE cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BRVE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $21.19 (52-wk range $17.86 - $32.00), any beat on forward guidance forces shorts and underweight funds to chase.